SHICHANG MIAO, Ph.D., Founder and president of CACO, is currently Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a Mountain View, California-based biotech company focusing on the discovery and development of drugs though regulation of chemokine receptors. Until May 2007, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He obtained his Ph.D. in organic chemistry/ natural products chemistry from the University of British Columbia (Vancouver , Canada ) in 1991 and carried out postdoctoral research in organic synthesis/natural products chemistry at the University of Alberta and in proteomics at the University of British Columbia. In 2001, he founded the Bay Area Analytical Chemists Network (the predecessor of CACO) and served as its chair through the end of 2004 and subsequently its scientific programs chair.